Different patient population and breast cancer subtypes are likely response to NACT differently and different biomarkers may be applied to patients with hormone receptor (HR)-positive/human epidermal growth factor 2 (HER2)-negative BC7. This evidence concerns the gene NR4A1 and breast cancer.